DRUGpreclinicalsmall molecule
praxis biotech sma protein synthesis
Brand names: Praxis-Biotech-SMA
Mechanism
Protein-synthesis modulator class. Unknown specific target. Likely candidate pathways: eIF2α phosphorylation or mTOR signaling, but not confirmed publicly.
Approved indications
SMA preclinical
Related claims (0)
No claims matched “praxis biotech sma protein synthesis” in free-text search.
Off-Target Findings (0)
No Boltz-2 / Chai-1 off-target panel claims recorded for this drug.